Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis

Efficacy of Vandetanib in Treating Locally Advanced or Metastatic Medullary Thyroid Carcinoma According to RECIST Criteria: A Systematic Review and Meta-Analysis

BackgroundVandetanib is the most largely used tyrosine kinase inhibitor (TKI) in patients with locally advanced and/or metastatic medullary thyroid cancer (MTC). Here, we conducted a systematic review on its efficacy and attempted to perform a meta-analysis adopting standardized RECIST criteria as e...

Full description

Bibliographic Details
Main Authors:	Pierpaolo Trimboli, Marco Castellana, Camilla Virili, Francesco Giorgino, Luca Giovanella
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2018-05-01
Series:	Frontiers in Endocrinology
Subjects:	medullary thyroid carcinoma tyrosine kinase inhibitors vandetanib RECIST systematic review meta-analysis
Online Access:	http://journal.frontiersin.org/article/10.3389/fendo.2018.00224/full

Similar Items

Polycythemia after vandetanib treatment in metastatic medullary thyroid carcinoma: A rare case report
by: Yusuf Ilhan, et al.
Published: (2020-12-01)

Cabozantinib, Vandetanib, Pralsetinib and Selpercatinib as Treatment for Progressed Medullary Thyroid Cancer with a Main Focus on Hypertension as Adverse Effect
by: Linnea Højer Wang, et al.
Published: (2023-01-01)

Apoferritin/Vandetanib Association Is Long-Term Stable But Does Not Improve Pharmacological Properties of Vandetanib
by: Kateřina Jáklová, et al.
Published: (2021-04-01)

Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both NF1 and Homozygous RET Proto-oncogen Germ-line Mutations
by: Begümhan Demir Gündoğan, et al.
Published: (2021-09-01)

Design and Synthesis of Vandetanib Derivatives Containing Nitroimidazole Groups as Tyrosine Kinase Inhibitors in Normoxia and Hypoxia
by: Huiqiang Wei, et al.
Published: (2016-12-01)

Evaluating vandetanib in the treatment of medullary thyroid cancer: patient-reported outcomes
by: Fallahi P, et al.
Published: (2019-08-01)

Targeted Therapy for Medullary Thyroid Cancer: A Review
by: S. R. Priya, et al.
Published: (2017-10-01)

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 2
by: Akshay D. Baheti, et al.
Published: (2019-08-01)

Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model
by: Silvia Carra, et al.
Published: (2021-03-01)

Comparison of RECIST 1.1 and iRECIST in Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
by: Hyo Jung Park, et al.
Published: (2021-01-01)

Vandetanib for Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Ling TAO, et al.
Published: (2012-03-01)

2012 European Thyroid Association Guidelines for Metastatic Medullary Thyroid Cancer
by: V V Voskoboynikov, et al.
Published: (2013-06-01)

Vandetanib Treatment in Refractory Advanced Lung Adenocarcinoma Patients:  Five Cases and Review of Literature
by: Lili GUO, et al.
Published: (2012-02-01)

Investigating the effect of vandetanib and celecoxib combination on angiogenesis
by: Abdul Qadir, MPhil, et al.
Published: (2023-10-01)

Radiosensitisation of Hepatocellular Carcinoma Cells by Vandetanib
by: Sami Znati, et al.
Published: (2020-07-01)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center
by: Ferhat FERHATOĞLU, et al.
Published: (2022-12-01)

Antineoplastic Effect of Lenvatinib and Vandetanib in Primary Anaplastic Thyroid Cancer Cells Obtained From Biopsy or Fine Needle Aspiration
by: Silvia Martina Ferrari, et al.
Published: (2018-12-01)

Passive Diffusion vs Active pH-Dependent Encapsulation of Tyrosine Kinase Inhibitors Vandetanib and Lenvatinib into Folate-Targeted Ferritin Delivery System
by: Skubalova Z, et al.
Published: (2021-01-01)

Tumor Response Criteria in Oncoimaging: RECIST Criteria and beyond—Part 1
by: Ashita Rastogi, et al.
Published: (2019-07-01)

Early Detection of Disease Progression in Metastatic Cancers: Could CTCs Improve RECIST Criteria?
by: Valentina Magri, et al.
Published: (2024-02-01)

Imaging biomarkers for evaluating tumor response: RECIST and beyond
by: Ching-Chung Ko, et al.
Published: (2021-07-01)

Tumor Response Evaluation Using iRECIST: Feasibility and Reliability of Manual Versus Software-Assisted Assessments
by: Inka Ristow, et al.
Published: (2024-02-01)

Molecular targeted therapies of aggressive thyroid cancer
by: Silvia Martina eFerrari, et al.
Published: (2015-11-01)

iRECIST: how to do it
by: Thorsten Persigehl, et al.
Published: (2020-01-01)

BUSCANDO UNA CURVA GENERAL DE RESPUESTA A LA QUIMIOTERAPIA BASADA EN LA EVALUACIÓN RADIOLÓGICA CON CRITERIO RECIST
by: Mauricio Canals L, et al.

Circulating tumor cells criteria (CyCAR) versus standard RECIST criteria for treatment response assessment in metastatic colorectal cancer patients
by: Mayte Delgado-Ureña, et al.
Published: (2018-09-01)

Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
by: Nils Degrauwe, et al.
Published: (2012-06-01)

An unusual cause of respiratory failure
by: Sahara N. Saltijeral, et al.
Published: (2020-09-01)

RECIST 1.1 and lesion selection: How to deal with ambiguity at baseline?
by: Antoine Iannessi, et al.
Published: (2021-03-01)

Recent Updates on the Management of Medullary Thyroid Carcinoma
by: Bo Hyun Kim, et al.
Published: (2016-09-01)

Vandetanib drives growth arrest and promotes sensitivity to imatinib in chronic myeloid leukemia by targeting ephrin type‐B receptor 4
by: Weina Ma, et al.
Published: (2022-07-01)

Automatic segmentation of hepatic metastases on DWI images based on a deep learning method: assessment of tumor treatment response according to the RECIST 1.1 criteria
by: Xiang Liu, et al.
Published: (2022-12-01)

Metastatic medullary thyroid carcinoma: A case report
by: Mitra Niafar, et al.
Published: (2011-01-01)

Breast metastasis from medullary thyroid carcinoma in a male patient: case report and review of the literature
by: Stylianos Mandanas, et al.
Published: (2015-05-01)

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study
by: Christina L. Addison, et al.
Published: (2015-06-01)

Update on Targeted Therapy in Medullary Thyroid Cancer
by: Christian Okafor, et al.
Published: (2021-08-01)

Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer
by: Davide Saronni, et al.
Published: (2022-09-01)

Twenty Years On: RECIST as a Biomarker of Response in Solid Tumours an EORTC Imaging Group – ESOI Joint Paper
by: Laure Fournier, et al.
Published: (2022-01-01)

Comparison between RECIST and PERCIST criteria in therapeutic response assessment in cases of lymphoma
by: Marwa Mohammed Hasan Tawfik, et al.
Published: (2020-05-01)

Response criteria in solid tumors (PERCIST/RECIST) and SUVmax in early-stage non-small cell lung cancer patients treated with stereotactic body radiotherapy
by: Cory Pierson, et al.
Published: (2018-02-01)